Evidence map›Paper›PMID 41579317›Full record

ArticleInflammopharmacology2026

Screening of active constituents in camellia oil against atopic dermatitis via molecular docking and experimental validation: elucidation of the underlying molecular mechanism.

Xin Chen, Quanchen Shen, Runcheng Zhou, Yueqiao Lin, Tong Zhou, Kecan Chen, Pengxue Wang, Yanman Chen, Hui Liu, Anping Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin Chen *Department of Clinical Laboratory Technology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Quanchen Shen *Department of Biotechnology and Engineering, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Runcheng Zhou *Department of Clinical Laboratory Technology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Yueqiao LinDepartment of Clinical Laboratory Technology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Tong ZhouDepartment of Clinical Laboratory Technology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Kecan ChenDepartment of Stomatology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Pengxue WangDepartment of Clinical Laboratory Technology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Yanman ChenDepartment of Clinical Laboratory Technology, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China.
Hui LiuDepartment of Pharmacy, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China. liuhuifs@fosu.edu.cn.
Anping YangDepartment of Pharmacy, School of Medicine, Foshan University, Foshan, 528225, Guangdong Province, China. foshanyap@fosu.edu.cn.

Funding

Foshan Academic-Industry Technology Transfer Support Program No. 2024SWYY05Foshan Science and Technology Innovation Project No.2320001007450
6 · The paper itself

Abstract

objectiveAtopic dermatitis (AD) is a chronic inflammatory skin disease. The JAK/STAT and PDE4/cAMP pathways are pivotal in driving its inflammation. This study aimed to discover natural JAK1 and PDE4 inhibitors from camellia oil to alleviate AD.

methodsUtilizing the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), we employed a target-based molecular docking approach against key inflammatory targets (JAK1, PDE4B, PDE4D) of AD to screen the compounds in camellia oil. This virtual screening was followed by in vitro enzymatic assays to validate their inhibitory effects. Based on these findings, we employed a DNCB-induced AD mouse model to compare the therapeutic efficacy of (1% and 4%) ( +)-catechin hydrate and (4% and 6%) epicatechin against 1.5% ruxolitinib cream.

resultsAlthough molecular docking screening predicted seven compounds with potential high binding affinity for PDE4B and PDE4D, respectively, subsequent in vitro enzymatic inhibition assays demonstrated that all of these compounds exhibited low inhibitory rates against the enzymes. In comparison, (+)-catechin hydrate and epicatechin not only exhibited excellent binding affinity with JAK1 but also achieved high inhibition rates. Their IC

conclusionIn camellia oil, (+)-catechin hydrate and epicatechin are the primary active constituents for the treatment of AD, suggesting that their anti-AD effects were possibly mediated through the suppression of the JAK1-driven inflammatory signaling pathway. This study not only provides a novel utilization strategy for camellia oil, but also offers new insights for the treatment of AD.

Indexed as

CamelliaDermatitis, AtopicPlant OilsAnimalsAnti-Inflammatory AgentsCatechinDisease Models, AnimalHumansJanus Kinase 1MiceMolecular Docking SimulationAnti-Inflammatory AgentsCatechinJanus Kinase 1Plant OilsAtopic dermatitisCamellia oil(+)-Catechin hydrateEpicatechinMolecular docking

Identifiers

PMID41579317

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.